Amyris Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amyris stock.
View analyst ratings for Amyris or view top-rated stocks.

Wall Street analysts have given Amyris a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amyris wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Amyris is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Amyris.

Amyris, Inc. (NASDAQ:AMRS) posted its earnings results on Thursday, May, 6th. The biotechnology company reported ($1.08) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.92. The biotechnology company had revenue of $176.90 million for the quarter, compared to analysts' expectations of $73.36 million. Amyris's revenue was up 507.9% on a year-over-year basis.
View Amyris' earnings history.

Amyris' stock was trading at $2.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMRS shares have increased by 414.9% and is now trading at $15.24.
View which stocks have been most impacted by COVID-19.

Amyris shares reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

Amyris issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $400 million-$400 million, compared to the consensus revenue estimate of $337.46 million.

6 Wall Street analysts have issued 1 year target prices for Amyris' stock. Their forecasts range from $3.35 to $35.00. On average, they expect Amyris' share price to reach $18.23 in the next year. This suggests a possible upside of 19.6% from the stock's current price.
View analysts' price targets for Amyris or view top-rated stocks among Wall Street analysts.

53 employees have rated Amyris CEO John Melo on Glassdoor.com. John Melo has an approval rating of 54% among Amyris' employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Amyris include Marathon Petroleum (MPC), Phillips 66 (PSX), Valero Energy (VLO), HollyFrontier (HFC), Renewable Energy Group (REGI), World Fuel Services (INT), Clean Energy Fuels (CLNE), PBF Energy (PBF), CVR Energy (CVI), Delek US (DK), Gevo (GEVO), Green Plains (GPRE), REX American Resources (REX) and Adams Resources & Energy (AE).
View all of AMRS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Amyris' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.38%), Pinnacle Associates Ltd. (1.38%), Lord Abbett & CO. LLC (0.97%), Geode Capital Management LLC (0.82%), Price T Rowe Associates Inc. MD (0.37%) and Millennium Management LLC (0.35%). Company insiders that own Amyris stock include Frank Kung, John Melo, L John Doerr and Patrick Y Yang.
View institutional ownership trends for Amyris.

AMRS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Millennium Management LLC, Victory Capital Management Inc., Morgan Stanley, MYDA Advisors LLC, Edmond DE Rothschild Holding S.A., Squarepoint Ops LLC, and Essex Investment Management Co. LLC.
View insider buying and selling activity for Amyris or view top insider-selling stocks.

AMRS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Lord Abbett & CO. LLC, Price T Rowe Associates Inc. MD, Baird Financial Group Inc., Renaissance Technologies LLC, Geode Capital Management LLC, Pinnacle Associates Ltd., and Voloridge Investment Management LLC. Company insiders that have bought Amyris stock in the last two years include Frank Kung, and L John Doerr.
View insider buying and selling activity for Amyris or or view top insider-buying stocks.

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRS stock can currently be purchased for approximately $15.24.

Amyris has a market capitalization of $4.50 billion and generates $173.14 million in revenue each year. The biotechnology company earns $-331,040,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

Amyris employs 595 workers across the globe.

The official website for Amyris is amyris.com.

Amyris is headquartered at 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]